<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33381">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01803919</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-SUR-2011-68</org_study_id>
    <secondary_id>112210</secondary_id>
    <nct_id>NCT01803919</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Antimicrobial Catheters to Avoid Urinary Infections in Spinal Cord Injured Patients</brief_title>
  <acronym>ESCALE</acronym>
  <official_title>Multicentric, Controlled, Randomized Clinical Trial to Assess the Efficacy and Cost-effectiveness of Urinary Catheters With Silver Alloy Coating Versus Conventional Catheters in Spinal Cord Injured Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asociacion Colaboracion Cochrane Iberoamericana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to make a comparison between the use of antiseptic silver
      alloy-coated silicone urinary catheters and the use of conventional silicone urinary
      catheters in spinal cord injured patients to prevent urinary infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antiseptic Silver Alloy-Coated Silicone Urinary Catheters seems to be a promising
      intervention to reduce urinary tract infections; however, research evidence cannot be
      extrapolated to spinal cord injured patients.

      The study is an open, randomized, multicentric, and parallel clinical trial with blinded
      assessment. The study includes spinal cord injured patients who require at least seven days
      of urethral catheterization as a method of bladder voiding. Participants are on-line
      centrally randomized and allocated to one of the two interventions (Antiseptic Urinary
      Catheters or Conventional Catheters). Catheters are used for a maximum period of 30 days or
      removed earlier at the clinician criteria.

      The main outcome is the incidence of urinary tract infections by the time of catheter
      removal or at day 30 after catheterization, the event that occurs first. Intention-to-treat
      analysis will be performed, as well as a primary analysis of all patients.

      The aim of this study is to assess whether silver alloy-coated silicone urinary catheters
      reduce urinary infections in spinal cord injured patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of catheter associated urinary tract infection</measure>
    <time_frame>at any time from catheterization procedure and 30th day, catheter removal or catheter replacement (whichever occurs first)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Is considered that a patient suffer a urinary tract infection if they have at least one suggestive sign or symptom with no other recognized cause and a positive urine culture with no more than 2 species of microorganisms.
An urinary tract infection is considered catheter associated if the specimen collection is performed at any time from catheterization procedure and 30th day, catheter removal or catheter replacement (whichever occurs first).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asymptomatic urinary tract infection</measure>
    <time_frame>at any time from catheterization procedure and 30th day, catheter removal or catheter replacement (whichever occurs first)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A positive urine culture with no more than 2 species of microorganisms(collected at any time from catheterization procedure and 30th day, catheter removal or catheter replacement, whichever occurs first), and no signs or symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteremic urinary tract infection</measure>
    <time_frame>at any time from catheterization procedure and 30th day, catheter removal or catheter replacement (whichever occurs first)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Those with the primary outcome and with a positive blood culture with at least 1 matching uropathogen microorganism to the urine culture.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Direct costs</measure>
    <time_frame>From catheterization procedure and 30th day, catheter removal or catheter replacement or finalization of complication(s) or related treatment(s), whichever last longer.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Calculation of direct costs attributable to the use of intervention or control urinary catheters and their complications</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events related to catheterization as a Measure of Safety and Tolerability</measure>
    <time_frame>at any time from catheterization procedure and 30th day, catheter removal or catheter replacement (whichever occurs first)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any untoward medical occurrence related to urinary catheterization</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">742</enrollment>
  <condition>Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Silver Alloy-Coated Urinary Catheters</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bactiguard® Infection Protection coating consists of noble metals such as gold, palladium and silver. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Urinary Catheter</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Conventional or standard urinary catheters are those commonly used in each study center, most of them made of silicone or silicone-latex. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Silver Alloy-Coated Urinary Catheters</intervention_name>
    <arm_group_label>Silver Alloy-Coated Urinary Catheters</arm_group_label>
    <other_name>BIP Foley catheter - Silicone Bactiguard Infection Protection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional Urinary Catheter</intervention_name>
    <arm_group_label>Conventional Urinary Catheter</arm_group_label>
    <other_name>Foley silicona 100% (16 or 18 Ch)</other_name>
    <other_name>Foley Rüsch (16 or 18 Ch)</other_name>
    <other_name>Foley Bardex (16 or 18 Ch)</other_name>
    <other_name>Folysil (16 or 18 Ch)</other_name>
    <other_name>Foley Rochester (16 or 18 Ch)</other_name>
    <other_name>Foley Euromedical (16 or 18 Ch)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with traumatic or medical spinal cord injury

          -  Age of 18 years or above

          -  Patients who need an indwelling urinary catheter as a method of bladder drainage for
             at least 7 days.

          -  Patients who are willing to participate in the study and give their written informed
             consent (If a patient is unable to give written consent because of physical or mental
             disability, an affirmation of consent will be taken in his presence from his relative
             or legal guardian).

        Exclusion Criteria:

          -  Patients who can benefit from other method of bladder drainage such as intermittent
             catheterization, suprapubic drainage, reflex voiding or use of an external collector.

          -  Patients with urinary tract infection at the moment of inclusion

          -  Current antibiotic use or use within 7 days prior to inclusion

          -  Outpatients with sporadic medical examinations (less than one per month)

          -  Known allergy to latex, silver salts or hydrogels.

          -  Patients with surgical interventions in the urinary tract that may interfere, at the
             investigator criteria, with the study results.

          -  Pregnant or breastfeeding woman.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Bonfill, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociacion Colaboracion Cochrane Iberoamericana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xavier Bonfill, MD, PhD</last_name>
    <phone>34 93 553 78 08</phone>
    <email>xbonfill@santpau.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Rigau, MD</last_name>
    <phone>34 93 553 78 08</phone>
    <email>drigau@santpau.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Bea</last_name>
      <email>manuel.bea@sespa.princast.es</email>
    </contact>
    <investigator>
      <last_name>Manuel Bea</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Neurorrehabilitación Instituto Guttmann</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albert Borau</last_name>
      <email>aborau@guttmann.com</email>
    </contact>
    <investigator>
      <last_name>Albert Borau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina M Alemán</last_name>
      <email>calesana@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Carolina M Alemán</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María L Jáuregui</last_name>
      <email>luisajauregui@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>María L Jáuregui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastián Salvador</last_name>
      <email>Sebastián.Salvador.de.la.Barrera@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Sebastián Salvador</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan R Espinosa</last_name>
      <email>juanr.espinosa.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Juan R Espinosa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Moraleda</last_name>
      <email>smoraledap.hulp@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Susana Moraleda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juana M Barrera</last_name>
      <email>juanam.barrera.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Juana M Barrera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional de Parapléjicos</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuel Esteban</last_name>
      <email>estebote@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Manuel Esteban</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luís Ledesma</last_name>
      <email>lledesma@salud.aragon.es</email>
    </contact>
    <investigator>
      <last_name>Luís Ledesma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://ensayoescale.com</url>
    <description>Click here for more information about this study: Multicentric,controlled,randomized clinical trial to assess the efficacy and cost-effectiveness of urinary catheters with silver alloy coating versus conventional catheters in spinal cord injured patient</description>
  </link>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>September 10, 2013</lastchanged_date>
  <firstreceived_date>February 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal cord injuries</keyword>
  <keyword>Urinary tract infection</keyword>
  <keyword>Urinary catheters</keyword>
  <keyword>Protocol</keyword>
  <keyword>Randomized clinical trial</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
